32,939 research outputs found
mj-will/nessai: v0.12.0a0
No full text<p>This is an alpha release of v0.12.0 of nessai.</p>
<p>This release is not intended for production use, and the changes here are not considered final.</p>
<p>The main changes in this pre-release are improvements to the importance nested sampler, most notably:</p>
<ul>
<li>final i.i.d samples can now be drawn during sampling rather than post sampling,</li>
<li>the sampler no longer requires the <code>to_unit_hypercube</code> method for sampling.</li>
</ul>
<p><strong>Full Changelog</strong>: https://github.com/mj-will/nessai/compare/v0.11.0...v0.12.0a0</p>
In vivo analysis of tyrosine hydroxylase expression cassettes in the 6-OHDA parkinsonian rat model using AAV vector: a repeated injection paradigm.
No full textmj-will/nessai: v0.12.0
No full text<p>Release of nessai v0.12.0</p>
<p>This release reworks large parts of the importance nested sampler to enable drawing i.i.d samples during sampling and remove the requirement for the <code>to_unit_hypercube</code> method.</p>
<p>The high-level API remains unchanged but the APIs for the <code>ImportanceNestedSampler</code> and <code>ImportanceFlowProposal</code> classes have changed. Existing runs of the importance nested sampler cannot be resumed with this version.</p>
<h2>Summary of changes</h2>
<ul>
<li>Explicitly support Python 3.12 (worked previously but was not tested)</li>
<li>Rework the importance nested sampler to support drawing i.i.d samples live and no longer require the <code>to_unit_hypercube</code> method</li>
<li>Changes to the importance nested sampler defaults</li>
<li>Standardize how sampling history is stored</li>
<li>Runs are now always seeded (randomly if a seed is not specified)</li>
<li>Fix two minor plotting bugs</li>
<li>Remove deprecated <code>max_threads</code> argument.</li>
</ul>
<p><a href="https://github.com/mj-will/nessai/blob/v0.12.0/CHANGELOG.md"><strong>Full Changelog</strong></a></p>
(a) Radiation (MJ m-2), (b) rainfall (mm), and (c) average temperature during the experimental period.
No full text<p>(a) Radiation (MJ m-2), (b) rainfall (mm), and (c) average temperature during the experimental period.</p
Heterogeneous and tissue-specific regulation of effector T cell responses by IFN-gamma during Plasmodium berghei ANKA infection.
No full textIFN-γ and T cells are both required for the development of experimental cerebral malaria during Plasmodium berghei ANKA infection. Surprisingly, however, the role of IFN-γ in shaping the effector CD4(+) and CD8(+) T cell response during this infection has not been examined in detail. To address this, we have compared the effector T cell responses in wild-type and IFN-γ(-/-) mice during P. berghei ANKA infection. The expansion of splenic CD4(+) and CD8(+) T cells during P. berghei ANKA infection was unaffected by the absence of IFN-γ, but the contraction phase of the T cell response was significantly attenuated. Splenic T cell activation and effector function were essentially normal in IFN-γ(-/-) mice; however, the migration to, and accumulation of, effector CD4(+) and CD8(+) T cells in the lung, liver, and brain was altered in IFN-γ(-/-) mice. Interestingly, activation and accumulation of T cells in various nonlymphoid organs was differently affected by lack of IFN-γ, suggesting that IFN-γ influences T cell effector function to varying levels in different anatomical locations. Importantly, control of splenic T cell numbers during P. berghei ANKA infection depended on active IFN-γ-dependent environmental signals--leading to T cell apoptosis--rather than upon intrinsic alterations in T cell programming. To our knowledge, this is the first study to fully investigate the role of IFN-γ in modulating T cell function during P. berghei ANKA infection and reveals that IFN-γ is required for efficient contraction of the pool of activated T cells
Self-compression of 4.9 µm pulses to sub-40 fs with 2 mJ energy in Zinc Sulfide
No full textNonlinear self-compression of few-cycle multi-mJ pulses at 4.9 µm in ZnS is presented. 80 fs input pulses are compressed to 37 fs with 2.1 mJ energy at a 1 kHz repetition rate. © 2024 The Author(s
Chemical composition (g/kg) and energy content (MJ/kg) of the diets used during the various phases of growth.
No full textChemical composition (g/kg) and energy content (MJ/kg) of the diets used during the various phases of growth.</p
Safety and efficacy of remimazolam versus propofol during EUS: a multicenter randomized controlled study
No full textBackground and Aims: Propofol, a widely used sedative in GI endoscopic procedures, is associated with cardiorespiratory suppression. Remimazolam is a novel ultrashort-acting benzodiazepine sedative with rapid onset and minimal cardiorespiratory depression. This study compared the safety and efficacy of remimazolam and propofol during EUS procedures. Methods: A multicenter randomized controlled study was conducted between October 2022 and March 2023 in patients who underwent EUS procedures. Patients were randomly assigned to receive either remimazolam or propofol as a sedative agent. The primary endpoint was cardiorespiratory adverse events (AEs) during the procedure, including desaturation, respiratory depression, hypotension, and tachycardia. Secondary endpoints were the time to achieve sedation, recovery time, quality of sedation, pain at the injection site, and satisfaction of both endoscopists and patients. Results: Four hundred patients enrolled in the study: 200 received remimazolam (10.8 ± 7.7 mg) and 200 received propofol (88.0 ± 49.1 mg). For cardiorespiratory AEs, the remimazolam group experienced fewer occurrences than the propofol group (8.5% vs 16%, P = .022). A nonsignificant trend was found toward less oxygen desaturation (1.0% vs 3.5%, P = .09), respiratory depression (.5% vs 1.5%, P = .62), hypotension (2.5% vs 5.5%, P = .12), and tachycardia (4.5% vs 5.5%, P = .68) with remimazolam than with propofol. Remimazolam showed a shorter induction time than propofol while maintaining comparable awakening and recovery times. Injection site pain was significantly lower in the remimazolam group than in the propofol group. The remimazolam group demonstrated a significantly higher quality of sedation and satisfaction scores than the propofol group, as evaluated by both endoscopists and patients. Conclusions: Remimazolam was superior to propofol in terms of safety and efficacy during EUS examinations. (Clinical trial registration number: KCT 0007643.
Effects of cardiac resynchronization therapy on myocardial contractile reserve during exercise.
No full textAimsMyocardial contractile reserve (MCR) is a marker of myocardial viability. The impact of cardiac resynchronization therapy (CRT) on MCR during exercise has been little studied. Our aim was to investigate the effects of CRT on global and regional MCR by exercise echocardiography.Methods and resultsTwenty-seven CRT responders (56 ischaemic) were assessed by echocardiography during rest and bicycle exercise. Images were acquired during spontaneous rhythm ('off) and active CRT ('on). Global MCR was expressed as the change (Δ) in left ventricular ejection fraction (LVEF) and aortic velocity-time integral (VTI) from rest to exercise. Regional MCR was expressed as the change in peak systolic tissue velocity (Sm) of the septum and lateral wall. Left ventricular ejection fraction and aortic VTI increased at 'on during rest and exercise, and the increase in global MCR during exercise was higher during 'on than 'off (Δ LVEF 6 ± 6 vs. 3 ± 3; P 0.009). Septum Sm increased during 'on at rest, and it was still higher during exercise (P≤ 0.01), although the absolute change from rest to exercise was similar during 'on and 'off. Lateral wall Sm did not change at rest during 'on, but basal lateral wall MCR during exercise was higher at 'on than 'off (P 0.036).ConclusionIn CRT responders, there is a pacing-dependent increase in global MCR during exercise. The changes in regional MCR of the septum and lateral wall show different patterns. These factors may help to understand the determinants of improved exercise tolerance in CRT responder
Effects of cardiac resynchronization therapy on myocardial contractile reserve during exercise.
No full textAimsMyocardial contractile reserve (MCR) is a marker of myocardial viability. The impact of cardiac resynchronization therapy (CRT) on MCR during exercise has been little studied. Our aim was to investigate the effects of CRT on global and regional MCR by exercise echocardiography.Methods and resultsTwenty-seven CRT responders (56 ischaemic) were assessed by echocardiography during rest and bicycle exercise. Images were acquired during spontaneous rhythm ('off) and active CRT ('on). Global MCR was expressed as the change (Δ) in left ventricular ejection fraction (LVEF) and aortic velocity-time integral (VTI) from rest to exercise. Regional MCR was expressed as the change in peak systolic tissue velocity (Sm) of the septum and lateral wall. Left ventricular ejection fraction and aortic VTI increased at 'on during rest and exercise, and the increase in global MCR during exercise was higher during 'on than 'off (Δ LVEF 6 ± 6 vs. 3 ± 3; P 0.009). Septum Sm increased during 'on at rest, and it was still higher during exercise (P≤ 0.01), although the absolute change from rest to exercise was similar during 'on and 'off. Lateral wall Sm did not change at rest during 'on, but basal lateral wall MCR during exercise was higher at 'on than 'off (P 0.036).ConclusionIn CRT responders, there is a pacing-dependent increase in global MCR during exercise. The changes in regional MCR of the septum and lateral wall show different patterns. These factors may help to understand the determinants of improved exercise tolerance in CRT responder
- …
